Real-world data show strong protection for U.S. infants As the United States navigates the 2024-2025 RSV season, several U.S. health networks published real-world analyses underscoring the protective effect of nirsevimab in infants. Across multiple settings, infants who received the preventive monoclonal antibody before RSV circulation experienced markedly lower rates of RSV-related hospitalizations compared with comparable…